Hyori Kim

Title: Hyori Kim: Innovator in Monoclonal Antibody Research

Introduction

Hyori Kim is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies. With a total of 9 patents to her name, her work has the potential to impact the diagnosis and treatment of various diseases.

Latest Patents

One of her latest patents is titled "Monoclonal antibody specifically binding to CCSP-2 and use thereof." This invention relates to a monoclonal antibody that specifically binds to an EGF2 domain of colon cancer secreted protein-2 (CCSP-2). The antibody or its antigen-binding fragment demonstrates significantly increased affinity and specificity compared to existing peptides and antibodies targeting CCSP-2. This advancement could lead to more accurate diagnoses through specific detection of CCSP-2 at the protein level. Another notable patent is "PDGF receptor antibody and use thereof," which involves an antibody against a PDGF receptor. This invention includes an antibody-drug conjugate that combines a chemotherapeutic agent with the PDGF receptor antibody, aimed at preventing or treating ocular neovascular diseases.

Career Highlights

Hyori Kim has worked with esteemed institutions such as Seoul National University and The Asan Foundation. Her research has been pivotal in advancing the understanding of monoclonal antibodies and their applications in medicine.

Collaborations

She has collaborated with notable colleagues, including Junho Chung and Soohyun Kim, contributing to a dynamic research environment that fosters innovation.

Conclusion

Hyori Kim's work in monoclonal antibody research exemplifies the impact of innovative thinking in the medical field. Her patents not only showcase her expertise but also hold promise for future advancements in disease diagnosis and treatment.